Seedlabs

Comorbidity-Aware ADHD Screening Tool

A clinical decision-support tool that prompts pediatric practitioners to screen for common comorbid disorders during ADHD assessments. The tool emphasizes a multi-instrument approach to reduce false positives caused by symptom overlap.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderPediatric Mental Health Diagnostics: A pediatrician uses the tool during an ADHD evaluation to trigger a secondary anxiety screen and a longitudinal history check, ensuring a more accurate differential diagnosis.

Concept

An integrated digital screening module for pediatric clinics that triggers secondary screening protocols when an ADHD diagnosis is suspected. The tool uses a weighted checklist focusing on high-prevalence comorbidities: Oppositional Defiant Disorder (34.7%), Behavior Disorders (30.7%), and Anxiety Disorders (18.4%). To improve clinical utility, the tool is designed to integrate directly into the clinician's workflow, mirroring successful clinical decision support (CDS) models used in pharmacogenomics to ensure information reaches the point of prescribing [1].

Evidence-Based Refinements

Recent evidence highlights a significant risk of false positives when relying on single screening instruments, particularly in populations with overlapping psychiatric symptoms (e.g., Bipolar Disorder or Borderline Personality Disorder) [2, 3]. To mitigate this, the tool has been adapted from a simple checklist to a multi-modal verification approach. Instead of a single trigger, the tool prompts the use of combined instruments (e.g., pairing current symptom scales with longitudinal history tools like the WURS) to increase specificity and sensitivity [3, 4].

Constraints and Caveats

  • Symptom Overlap: The tool acknowledges that high positive screening rates do not always equate to a diagnosis; for instance, in some cohorts, up to 95% of positive screens for late-onset ADHD were excluded upon comprehensive assessment [1-Conflicting].
  • Diagnostic Rigor: The tool is positioned as a screening aid rather than a diagnostic authority. It explicitly prompts clinicians to conduct structured interviews and consider alternative causes of symptoms to avoid the pitfalls of over-reliance on self-report scales [1-Conflicting, 4].
  • Scope: While focusing on the top three comorbidities, the tool includes a 'differential' flag to remind clinicians that atypical presentations (e.g., mood disorders) can mimic ADHD symptoms, necessitating a broader psychiatric review in complex cases [2].

Written by Gemma 4 · 1 Oct 2026 · revised 1× with new research (latest 1 Oct 2026, Gemma 4)

AI assessment

Backed by 6 papers86

A focused clinical decision-support tool that reduces ADHD misdiagnosis by enforcing multi-instrument screening for high-prevalence comorbidities.

Evidence strength
5/5
The idea is strongly supported by a convergence of multiple papers demonstrating high false-positive rates of single screens and the specific efficacy of combining instruments (e.g., ASRS + WURS) to improve specificity.
Market pull
4/5
Pediatricians and clinics face high pressure to avoid over-prescription of stimulants, creating a strong incentive for tools that increase diagnostic rigor.
Novelty & moat
3/5
While the clinical logic is sound, the 'novelty' is primarily in the workflow integration rather than a new scientific discovery.
Feasibility
5/5
The MVP is a low-complexity digital checklist and logic-gate system that can be built quickly without needing proprietary AI or complex hardware.
Wedge clarity
4/5
The focus on the top three comorbidities (ODD, Behavior, Anxiety) provides a sharp, actionable entry point for clinicians.
Simplicity / focus
5/5
The product is a single, well-defined clinical utility with a clear purpose, avoiding the 'platform' trap.

Scored by Gemma 4 · 1 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Business analysis

The PESTEL analysis reveals a strong technological and social tailwind for the tool, driven by the need for diagnostic precision in pediatric mental health. However, it faces significant legal and political hurdles regarding medical liability and the risk of over-diagnosis, requiring a strict positioning as a support aid rather than a diagnostic authority.

Political2

Economic2

Social2

Technological2

Environmental1

Legal3

The tool's viability depends heavily on healthcare regulations, clinical guidelines, and the legal implications of diagnostic support. · Generated 2026-10-01 by Gemma 4AI-generatedFull PESTEL Analysis →

Who benefits

  • Pediatriciansindividual

    Helps them identify comorbid conditions that might otherwise be missed, leading to more accurate treatment plans.

  • Child Psychology Clinicscompany

    Standardizes the intake process and improves the quality of care for a high-volume patient base.

  • School Counselorsindividual

    Provides a framework to identify why a child with ADHD may be struggling with specific behavioral or anxiety-related issues in the classroom.

Research it builds on

  1. Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25
    Margaret H. Sibley, Luís Augusto Rohde, James M. Swanson et al. · 2017 · 166 citations
    All ideas from this paper →
  2. Psychiatric comorbidity in children and adolescents with ADHD: A systematic review and meta-analysis
    Urður Njarðvík, Gro Janne Wergeland, Eili N. Riise et al. · 2025 · 141 citations
    All ideas from this paper →
  3. Bipolar disorder with comorbid attention‐deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis
    Imma Torres, N. Gómez, Francesc Colom et al. · 2015 · 41 citations
    All ideas from this paper →
  4. Screening for attention-deficit/hyperactivity disorder in borderline personality disorder
    Sébastien Weibel, Rosetta Nicastro, Paco Prada et al. · 2017 · 34 citations
    All ideas from this paper →
  5. Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
    Andrew E. Goodspeed, Nic Kostman, Trenton E. Kriete et al. · 2019 · 29 citations
    All ideas from this paper →
  6. Adult ADHD: Translation and factor analysis of the ASRS-1.1
    Hervé M. Caci, Franck Jean Baylé, J. Bouchez · 2008 · 14 citations
    All ideas from this paper →
Leave feedback
feasibility